Park National Corp OH Has $7.33 Million Stock Position in Becton, Dickinson and Company $BDX

Key Points

• Park National Corp OH increased its holdings in Becton, Dickinson and Company by 11.3% during the 2nd quarter, owning 42,578 shares worth $7.33 million.
• Institutional investors now own 86.97% of Becton, Dickinson's stock, with notable increases from firms like Vanguard Group and T. Rowe Price.
• Becton, Dickinson reported $3.68 EPS for the latest quarter, exceeding estimates, while also declaring a quarterly dividend of $1.04 per share.

Park National Corp OH boosted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 11.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 42,578 shares of the medical instruments supplier's stock after acquiring an additional 4,322 shares during the quarter. Park National Corp OH's holdings in Becton, Dickinson and Company were worth $7,334,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its position in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after acquiring an additional 877 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of Becton, Dickinson and Company by 50.6% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock worth $18,808,000 after acquiring an additional 27,581 shares during the last quarter. FORA Capital LLC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter worth $3,458,000. Foster Victor Wealth Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter worth $6,406,000. Finally, GAMMA Investing LLC grew its stake in shares of Becton, Dickinson and Company by 29.9% in the first quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock worth $744,000 after acquiring an additional 748 shares during the last quarter. Institutional investors own 86.97% of the company's stock.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. The trade was a 19.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Claire Fraser sold 917 shares of the business's stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares of the company's stock, valued at $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,965 shares of company stock valued at $551,536 over the last quarter. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Trading Up 0.3%

Shares of BDX stock traded up $0.51 on Tuesday, reaching $186.25. The company had a trading volume of 1,211,488 shares, compared to its average volume of 1,651,059. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The stock has a market cap of $53.38 billion, a PE ratio of 13.02, a PEG ratio of 1.50 and a beta of 0.27. The company has a 50-day moving average of $186.72 and a 200-day moving average of $190.98. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. The company had revenue of $5.51 billion during the quarter, compared to analysts' expectations of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.Becton, Dickinson and Company's revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the business posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be given a $1.04 dividend. The ex-dividend date is Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company's payout ratio is currently 74.82%.

Analyst Ratings Changes

Several brokerages have recently issued reports on BDX. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Morgan Stanley lifted their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Barclays decreased their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 3rd. Citigroup downgraded shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and decreased their price target for the stock from $217.00 to $185.00 in a research note on Thursday, May 22nd. Finally, Piper Sandler restated a "neutral" rating and issued a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Four investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $211.44.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.